Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial

Joseph Gligorov(Sorbonne Université), Dinesh Doval(Rajiv Gandhi Cancer Institute and Research Centre), José Bines(Instituto Nacional do Câncer), Emilio Alba(Hospital Clínico Universitario Virgen de la Victoria), Paulo Cortes(Hospital de Santa Maria), Jean‐Yves Pierga(Université Paris Cité), Vineet Govinda Gupta, Romulo de Paula Costa(Instituto do Câncer do Estado de São Paulo), Stefanie Srock(Roche (Switzerland)), Sabine de Ducla(Roche (Switzerland)), Ulrich Freudensprung(Roche (Switzerland)), Giorgio Mustacchi(University of Trieste)
The Lancet Oncology
September 28, 2014
10.1016/s1470-2045(14)70444-9
Cited by 127

Abstract

Related Papers

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Kathy D. Miller, Molin Wang, Julie R. Gralow et al.|New England Journal of Medicine|2007|3k
A note on quantifying follow-up in studies of failure time
M. Schemper, Terry L. Smith|Controlled Clinical Trials|1996|2.5k
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
Jaafar Bennouna, Javier Sastre, Dirk Arnold et al.|The Lancet Oncology|2012|1.2k
RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer
Nicholas J. Robert, Véronique Dièras, John A. Glaspy et al.|Journal of Clinical Oncology|2011|1.1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
David Miles, Arlene Chan, Luc Dirix et al.|Journal of Clinical Oncology|2010|886